Human FHL1 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB5938
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Immunocytochemistry, Western Blot
Cited:
Immunocytochemistry
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2B Clone # 767418
Product Specifications
Immunogen
E. coli-derived recombinant human FHL1
Thr93-Asn166
Accession # Q13642
Thr93-Asn166
Accession # Q13642
Specificity
Detects human FHL1 in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Scientific Data Images for Human FHL1 Antibody
Detection of Human FHL1 by Western Blot.
Western blot shows lysates of human skeletal muscle tissue and human heart tissue. PVDF membrane was probed with 0.2 µg/mL of Mouse Anti-Human FHL1 Monoclonal Antibody (Catalog # MAB5938) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for FHL1 at approximately 34 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
FHL1 in SH‑SY5Y Human Cell Line.
FHL1 was detected in immersion fixed SH-SY5Y human neuroblastoma cell line using Mouse Anti-Human FHL1 Monoclonal Antibody (Catalog # MAB5938) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counter-stained with DAPI (blue). Specific staining was localized to nuclei and cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.Applications for Human FHL1 Antibody
Application
Recommended Usage
Immunocytochemistry
8-25 µg/mL
Sample: Immersion fixed SH‑SY5Y human neuroblastoma cell line
Sample: Immersion fixed SH‑SY5Y human neuroblastoma cell line
Western Blot
0.2 µg/mL
Sample: Human skeletal muscle tissue and human heart tissue
Sample: Human skeletal muscle tissue and human heart tissue
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Sterile PBS to a final concentration of 0.5 mg/mL. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: FHL1
FHL1 (Four-and-a-half LIM domains protein 1; also SLIM1 and KyoT1) is an approximately 35 kDa member of the four-and-a half class of the LIM domain-only protein family. It is highly expressed in myocardium and skeletal muscle, and is now known to bind NFATc1, promoting muscle hypertrophy. It is also noted to be a RIP140 binding partner that inhibits estrogen receptor signaling. Human FHL1 is 323 amino acids (aa) in length. It contains one C4-type Zn-finger region (aa 7-31), three distinct LIM domains (aa 40-77; 101-158; 162-212) and a bipartite NLS (aa 231-246). There is one 32 kDa splice variant that shows a 50 aa substitution for aa 231-323. This creates a fourth LIM domain. There are also alternative start sites 29 aa and 16 aa upstream of the standard site, a deletion of aa 168-296, and an 11 aa substitution for aa 81-91. Over aa 93-166, human FHL1 is 97% aa identical to mouse FHL1.
Long Name
Four and a Half LIM Domains Protein 1
Alternate Names
HLH1, HPLH1, KYOT, SLIM1, SLIMMER, XMPMA
Gene Symbol
FHL1
UniProt
Additional FHL1 Products
Product Documents for Human FHL1 Antibody
Product Specific Notices for Human FHL1 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...